<DOC>
	<DOCNO>NCT02665234</DOCNO>
	<brief_summary>The purpose study assess safety efficacy Tavilermide Ophthalmic Solution compare Placebo Ophthalmic Solution treat sign symptom dry eye disease .</brief_summary>
	<brief_title>A Safety Efficacy Study Tavilermide ( MIM-D3 ) Ophthalmic Solution Treatment Dry Eye Disease</brief_title>
	<detailed_description />
	<mesh_term>Eye Diseases</mesh_term>
	<mesh_term>Keratoconjunctivitis</mesh_term>
	<mesh_term>Keratoconjunctivitis Sicca</mesh_term>
	<mesh_term>Dry Eye Syndromes</mesh_term>
	<mesh_term>Pharmaceutical Solutions</mesh_term>
	<mesh_term>Ophthalmic Solutions</mesh_term>
	<criteria>Be least 18 year age . Provided write informed consent . Have report history dry eye Have history use desire use eye drop dry eye Be diagnose ongoing ocular infection ( bacterial , viral , fungal ) Visit 1 . Be diagnose ocular rosacea , viral bacterial disease cornea conjunctiva , within last 12 month . Have plan ocular and/or lid surgery study period . Have correct visual acuity great equal +0.7 assess Early Treatment Diabetic Retinopathy Study ( ETDRS ) scale eye Visit . Have uncontrolled systemic disease . Be woman pregnant , nurse planning pregnancy . Be woman childbearing potential use acceptable mean birth control Have know allergy and/or sensitivity test article component . Have condition situation investigator feel may put subject significant risk , may confound study result , may interfere significantly subject 's participation study Be currently enrol investigational drug device study use investigational drug device within 45 day Visit 1 Be unable unwilling follow instruction , include participation study assessment visit</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>Dry Eye</keyword>
</DOC>